Daniel J Tenney

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi request reprint Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
    Richard J Colonno
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    Hepatology 44:1656-65. 2006
  2. pmc Inhibition of hepatitis B virus polymerase by entecavir
    David R Langley
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06443, USA
    J Virol 81:3992-4001. 2007
  3. pmc Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
    D J Tenney
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Pkwy, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 48:3498-507. 2004
  4. doi request reprint Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies
    Daniel J Tenney
    Bristol Myers Squibb Research and Development, Wallingford, CT, USA
    Antivir Ther 15:529-35. 2010
  5. pmc Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present
    Daniel J Tenney
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 51:902-11. 2007
  6. doi request reprint Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy
    Daniel J Tenney
    Bristol Myers Squibb Company Research and Development, Wallingford, CT 06492, USA
    Hepatology 49:1503-14. 2009
  7. doi request reprint Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response
    Carl J Baldick
    Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
    J Hepatol 48:895-902. 2008
  8. pmc Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates
    Jie Fang
    Bristol Myers Squibb Research and Development, Wallingford, CT, USA
    Antimicrob Agents Chemother 53:2762-72. 2009
  9. doi request reprint Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance
    Carl J Baldick
    Bristol Myers Squibb Research and Development, Wallingford, CT 06492, USA
    Hepatology 47:1473-82. 2008
  10. pmc Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition
    Charles E Mazzucco
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 52:598-605. 2008

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
    Richard J Colonno
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    Hepatology 44:1656-65. 2006
    ..These findings suggest that the rapid, sustained suppression of HBV replication, combined with a requirement for multiple substitutions, creates a high genetic barrier to ETVr in nucleoside naïve patients...
  2. pmc Inhibition of hepatitis B virus polymerase by entecavir
    David R Langley
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06443, USA
    J Virol 81:3992-4001. 2007
    ..Overall, these studies explain the potency, mechanism, and cross-resistance profile of ETV against HBV and account for the successful treatment of naive and LVD- or ADV-experienced chronic HBV patients...
  3. pmc Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
    D J Tenney
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Pkwy, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 48:3498-507. 2004
    ..In summary, infrequent ETV resistance can emerge during prolonged therapy, with selection of additional RT substitutions within a 3TC(r) HBV background, leading to reduced ETV susceptibility and treatment failure...
  4. doi request reprint Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies
    Daniel J Tenney
    Bristol Myers Squibb Research and Development, Wallingford, CT, USA
    Antivir Ther 15:529-35. 2010
    ..The scheme takes into account the need for rapid analysis of large numbers of clinical isolates through nucleotide sequencing and methods for phenotypic validation using cell culture and in vitro enzyme immunoassay formats...
  5. pmc Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present
    Daniel J Tenney
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 51:902-11. 2007
    ..In summary, ETV was effective in LVD-refractory patients, with resistant sequences arising from a subset of patients harboring preexisting LVDr/ETVr variants and with approximately half of the patients experiencing a virologic rebound...
  6. doi request reprint Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy
    Daniel J Tenney
    Bristol Myers Squibb Company Research and Development, Wallingford, CT 06492, USA
    Hepatology 49:1503-14. 2009
    ..These findings support ETV as a primary therapy that enables prolonged treatment with potent viral suppression and minimal resistance...
  7. doi request reprint Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response
    Carl J Baldick
    Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
    J Hepatol 48:895-902. 2008
    ..Using >500 patient HBV isolates from several entecavir clinical trials, we show that phenotypic susceptibility correlates with genotypic resistance and patient virologic responses...
  8. pmc Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates
    Jie Fang
    Bristol Myers Squibb Research and Development, Wallingford, CT, USA
    Antimicrob Agents Chemother 53:2762-72. 2009
    ..In summary, we established and validated an ultrasensitive method for measuring resistant HBV variants in clinical specimens, which enabled earlier, quantitative measurement of resistance to therapy...
  9. doi request reprint Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance
    Carl J Baldick
    Bristol Myers Squibb Research and Development, Wallingford, CT 06492, USA
    Hepatology 47:1473-82. 2008
    ....
  10. pmc Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition
    Charles E Mazzucco
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 52:598-605. 2008
    ..In summary, cell culture and enzymatic studies yielded no evidence that would predict mitochondrial toxicity of ETV at exposure levels in excess of those expected to be achieved clinically...
  11. pmc High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus
    Michael J Wichroski
    Bristol Myers Squibb Research and Development, Wallingford, Connecticut, United States of America
    PLoS ONE 7:e42609. 2012
    ..Leveraging results from this robust whole-virus assay represents a critical first step towards identifying inhibitors of novel targets to broaden the spectrum of antivirals for the treatment of HCV...
  12. doi request reprint Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks
    Morris Sherman
    Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada
    Hepatology 48:99-108. 2008
    ..CONCLUSION: Through 96 weeks of treatment, 1 mg entecavir resulted in continued clinical benefit in lamivudine-refractory HBeAg-positive chronic hepatitis B patients with a safety profile comparable to lamivudine...